The Cost of Doing Business

Hey , The headline below to the naked eye looks normal…     Oppenheimer turns bullish on Comcast catalysts   After all, Wall Street analysts issue new buy and sell recommendations— EVERY DAY. But do you know what else? Some of these analysts are rotten. And I’m not talking about their analysis.  You see, Wall Street Insiders aren’t the only ones playing the game with loaded dice—so are the big investment banks that the public relies on for research and recommendations.   How do I know this? Simple. That headline that I shared with you above, well… I was actually able to get into the Comcast trade before the bullish call by Oppenheimer.     “A big player stepped in and scooped up every contract they could get their hands on these $46 calls at $0.34.” My Dollar Ace strategy revolves around flagging down large and unusual options activity.  I have a proprietary options scanner that helps me find these big bet option trades, and thus far, the results have been nothing short of phenomenal.     I don’t have any family and friends that work at Oppenheimer. I didn’t need it, all I needed was the Dollar Ace scanner.  And do you know what else? This type of stuff happens ALL THE TIME.  Why? Because Wall Street analysts are littered with conflicts of interest.  Analysts are incentivized to give bullish recommendations, especially if the investment bank they work for is doing business with that company.  For example, let’s say a company wants to hire an investment bank to help them with underwriting new issues of stock.    Do you really think that the bank will jeopardize that relationship by having one of its analysts come out and give a SELL recommendation? Heck no.  Or how about this one…  Let’s say an investment bank is trying to drum up new business. Companies are more likely to hire them if they have a reputation for sending out bullish and favorable reports.    Of course, in theory, none of this is supposed to matter. That’s because banks set up “Chinese Walls” to eliminate the conflict of interest between them and the analysts.  But as you can see from the Oppenheimer trade… that’s almost never the case.  These banks and analysts are spoiled rotten.  As a trader— you have two options.  You can complain about it and scream The game is rigged.  Find a way to track their moves, and profit alongside them.  I have chosen the latter. And you should too.     My Dollar Ace service stalks the biggest, baddest, and most profitable options traders in the world. My scanner tells me what they’re trading, how much they are expecting the stock to move by, and by when.  The only thing it doesn’t tell me is—why.  We usually don’t find that out until after the fact… like the Comcast upgrade. But by that time, we’re peeling off positions for a profit.  With the market at all-time highs, finding alpha is getting even harder for the bulge bracket investment banks.  So it’s no surprise to see some of these shady insider option trades going off as these bad-apple analysts resort to tactics that are unethical and potentially illegal.  It happens all the time…  Why not try to fill your pockets next time it does? That said, I’m going to make this a really easy decision for you.  For a limited time, you can join Dollar Ace at its Founding Members price. That’s a 60-70% discount, from what it normally goes for (not including the bonuses). See you on the other side! Cheers to Profits!     Kyle Dennis           RagingBull, LLC 62 Calef Hwy. #233, Lee, NH 03861 Stop receiving exclusive emails from Kyle Dennis Neither Kyle Dennis nor RagingBull.com, LLC (publisher of BiotechBreakouts) is registered as an investment adviser nor a broker/dealer with either the U. S. Securities & Exchange Commission or any state securities regulatory authority. Users of this website are advised that all information presented on this website is solely for informational purposes, is not intended to be used as a personalized investment recommendation, and is not attuned to any specific portfolio or to any user's particular investment needs or objectives. The owners, employees and writers of RagingBull.com may engage in securities trading that is discussed or viewed on this website, but all such individuals are buying and selling such securities for their own account. These individuals do not engage in any trades with customers. The buying and selling of securities by these individuals is not part of a regular business of buying and selling securities. Past performance is NOT indicative of future results. Furthermore, such information is not to be construed as an offer to sell or the solicitation of an offer to buy, nor is it to be construed as a recommendation to buy, hold or sell (short or otherwise) any security. All users of this website must determine for themselves what specific investments to make or not make and are urged to consult with their own independent financial advisors with respect to any investment decision. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. All opinions, analyses and information included on this website are based on sources believed to be reliable and written in good faith, but should be independently verified, and no representation or warranty of any kind, express or implied, is made, including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. In addition, we undertake no responsibility to notify such opinions, analyses or information or to keep such opinions, analyses or information current. Also be aware that owners, employees and writers of and for RagingBull.com, LLC may have long or short positions in securities that may be discussed on this website or newsletter, but all such positions are held for such representative’s own account. Past results are not indicative of future profits. This table is accurate, though not every trade is represented. Profits and losses reported are actual figures from the portfolios Kyle Dennis manages on behalf of RagingBull.com, LLC. If you have a current active subscription with Biotech Breakouts you will need to contact us here if you want to cancel your subscription. Opting out of emails does not remove you from your service at BiotechBreakouts.com. Unsubscribe from all RagingBull Emails